Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,256 | 164 | 96.0% |
| Education | $115.90 | 3 | 3.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.00 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $787.66 | 33 | $0 (2024) |
| PFIZER INC. | $323.97 | 19 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $311.11 | 18 | $0 (2024) |
| QOL Medical, LLC | $300.08 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $251.62 | 10 | $0 (2024) |
| GENZYME CORPORATION | $187.61 | 10 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $177.59 | 12 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $155.69 | 9 | $0 (2024) |
| Covidien LP | $125.00 | 1 | $0 (2019) |
| Medtronic, Inc. | $116.67 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,685 | 93 | ABBVIE INC. ($386.42) |
| 2023 | $545.49 | 34 | Regeneron Healthcare Solutions, Inc. ($85.81) |
| 2022 | $878.58 | 35 | ABBVIE INC. ($339.54) |
| 2021 | $14.99 | 1 | VIVUS LLC ($14.99) |
| 2020 | $53.08 | 3 | Olympus America Inc. ($27.32) |
| 2019 | $125.00 | 1 | Covidien LP ($125.00) |
| 2017 | $89.77 | 1 | Alexion Pharmaceuticals, Inc. ($89.77) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 2 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Immunology | ||||||
| 10/02/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/01/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/01/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: LIVER DISEASE | ||||||
| 09/30/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: VIROLOGY | ||||||
| 09/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Immunology | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: LIVER DISEASE | ||||||
| 09/25/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/10/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $11.38 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Education | In-kind items and services | $8.45 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/30/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/29/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $15.85 | General |
| Category: THERAPY FOR CSID | ||||||
| 08/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Gastroenterology | ||||||
| 08/28/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $7.40 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $19.69 | General |
| Category: GI | ||||||
| 08/15/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Education | In-kind items and services | $8.45 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $7.22 | General |
| Category: Immunology | ||||||
| 08/13/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/12/2024 | Ferring Pharmaceuticals Inc. | CLENPIQ (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/05/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Rare Disease | ||||||
| 07/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 313 | 373 | $203,985 | $32,078 |
| 2022 | 17 | 769 | 1,007 | $611,760 | $92,908 |
| 2021 | 2 | 61 | 93 | $26,382 | $6,985 |
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 84 | 122 | $28,060 | $7,981 | 28.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 47 | 49 | $21,462 | $5,317 | 24.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 14 | 15 | $28,463 | $3,303 | 11.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 33 | $10,956 | $3,273 | 29.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 40 | $9,400 | $2,681 | 28.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 17 | $10,737 | $2,457 | 22.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 36 | 36 | $57,420 | $2,454 | 4.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 26 | $9,074 | $2,252 | 24.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $8,448 | $1,906 | 22.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $19,965 | $454.91 | 2.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 130 | 138 | $60,444 | $14,918 | 24.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 137 | 246 | $56,580 | $14,388 | 25.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 98 | 158 | $52,456 | $12,941 | 24.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 36 | 38 | $72,105 | $8,066 | 11.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 68 | $23,732 | $6,690 | 28.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 72 | 76 | $121,220 | $5,973 | 4.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 21 | 31 | $22,134 | $5,630 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 69 | $16,215 | $5,025 | 31.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $13,000 | $3,507 | 27.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $10,120 | $2,888 | 28.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 29 | 29 | $10,208 | $2,698 | 26.4% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 12 | 14 | $24,255 | $2,324 | 9.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 18 | 18 | $30,492 | $2,252 | 7.4% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2022 | 17 | 17 | $30,855 | $1,881 | 6.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 28 | 28 | $50,820 | $1,849 | 3.6% |
About Dr. Shefali Shah, M.D
Dr. Shefali Shah, M.D is a Internal Medicine healthcare provider based in Oakhurst, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2015. The National Provider Identifier (NPI) number assigned to this provider is 1720469950.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shefali Shah, M.D has received a total of $3,392 in payments from pharmaceutical and medical device companies, with $1,685 received in 2024. These payments were reported across 168 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($3,256).
As a Medicare-enrolled provider, Shah has provided services to 1,143 Medicare beneficiaries, totaling 1,473 services with total Medicare billing of $131,971. Data is available for 3 years (2021–2023), covering 29 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location Oakhurst, NJ
- Active Since 06/12/2015
- Last Updated 03/06/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1720469950
Products in Payments
- RINVOQ (Biological) $377.32
- DUPIXENT (Biological) $343.30
- XELJANZ (Drug) $256.54
- SUCRAID (Drug) $221.42
- ENTYVIO (Biological) $199.12
- SKYRIZI (Biological) $157.32
- TREMFYA (Drug) $152.62
- XIFAXAN (Drug) $150.89
- Barrx (Device) $125.00
- INTERSTIM (Device) $116.67
- STELARA (Biological) $99.00
- EOHILIA (Drug) $97.52
- DIFICID (Drug) $93.04
- Kanuma (Drug) $89.77
- CREON (Drug) $89.40
- Sucraid (Drug) $78.66
- ZEPOSIA (Drug) $71.20
- VELSIPITY (Drug) $67.43
- RESMETIROM (Drug) $67.03
- LINZESS (Drug) $63.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Oakhurst
Dr. John Ciciarelli, Md, MD
Internal Medicine — Payments: $42,609
Dr. Aleksey Kretov, Md, MD
Internal Medicine — Payments: $18,333
Charles Peeples, Md, MD
Internal Medicine — Payments: $9,690
Dr. Richard Mojares, M.d, M.D
Internal Medicine — Payments: $6,285
Dr. Dharmesh Kaswala, Md, MD
Internal Medicine — Payments: $6,113
Reza Akhtar, Md, MD
Internal Medicine — Payments: $6,097